Biotech News Alert: GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference
50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months
SAN ANTONIO - September 8, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing ... Read more
Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients
SAN ANTONIO - October 9, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that patient enrollment has been completed in the ... Read more